Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Forte Biosciences, Inc.NASDAQ: FBRX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $3.18M rose 96.1% year over year, behind the +99.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 90.9% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +96.1% toward the trailing-twelve-month pace of +99.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.26M USD
- Year-over-year change
- +102.2%
- 4-year CAGR
- +10.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.26M | +102.2% |
| FY2024 | 2024-12-31 | 3.1M | -5.8% |
| FY2023 | 2023-12-31 | 3.28M | -18.2% |
| FY2022 | 2022-12-31 | 4.02M | -4.7% |
| FY2021 | 2021-12-31 | 4.21M | — |
Stock-Based Compensation vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +99.9% is the 2nd highest of 10, against a peer median of -5.6%.
- Over three fiscal years its annual growth of +15.9% compares with a peer median of +3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.47M USD | -43.3% | -31.8% | 340.0% | |
| LTM Mar 2026 | $21.22M USD | -43.4% | -16.7% | 115.2% | |
| LTM Mar 2026 | $10.03M USD | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $7.82M USD | +99.9% | +15.9% | — | |
| LTM Mar 2026 | $7.62M USD | -49.8% | -20.2% | — | |
| LTM Mar 2026 | $6.49M USD | -5.6% | +3.2% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $6.28M USD | +111.2% | +109.9% | — |
| LTM Mar 2026 | $5.99M USD | +19.7% | +10.2% | 1140.6% | |
| LTM Mar 2026 | CHF 4.21M CHF | -4.1% | -4.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.05M USD | +83.8% | +67.0% | — |
| Peer median (excluding FBRX) | — | -5.6% | +3.2% | 340.0% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.71M) | (13.88M) | (31.48M) | (35.48M) | (69.38M) |
| Depreciation & Amortization | 36K | 0 | 9K | 39K | 64K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 1.04M |
| Stock-Based Compensation | 4.21M | 4.02M | 3.28M | 3.1M | 6.26M |
| Change in Working Capital | 720K | 1.68M | (392K) | 1.76M | 11.37M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (294K) | 207K | 271K | 3.02M | 5.54M |
| Other Working Capital | 1.01M | 1.47M | (663K) | (1.26M) | 5.83M |
| Other Non-Cash Items | 61K | 0 | (131K) | (158K) | (237K) |
| Operating Cash Flow | (16.68M) | (8.19M) | (28.71M) | (30.75M) | (50.88M) |
| Capital Expenditures | 0 | 0 | (88K) | (37K) | (116K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (9.97M) | (35.96M) | 0 |
| Sales of Investments | 0 | 0 | 10.1M | 0 | 36.35M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 47K | (35.99M) | 36.23M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 62K | 7.23M | 24.74M | 53M | 76.83M |
| Common Stock Repurchased | 0 | 0 | 0 | (1K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (106K) | 12K | (44K) | (1.14M) | (7.47M) |
| Financing Cash Flow | (44K) | 7.24M | 24.68M | 51.86M | 69.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (16.72M) | (944K) | (3.98M) | (14.88M) | 54.71M |
| Free Cash Flow | (16.68M) | (8.19M) | (28.79M) | (30.78M) | (51M) |
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.